|
Forecast Period
|
2026-2030
|
|
Market Size (2024)
|
USD 95.47 Million
|
|
Market Size (2030)
|
USD 134.83 Million
|
|
CAGR (2025-2030)
|
5.88%
|
|
Fastest Growing Segment
|
Hematology Analyzers
|
|
Largest Market
|
Kanto
|
Market Overview
Japan Haematology Market was valued at USD 95.47 Million in 2024 and is expected to reach USD 134.83 Million
by 2030 with a CAGR of 5.88% during the forecast period. The Japan hematology
market is being driven by several key factors. Advances in diagnostic
technologies, such as next-generation sequencing and molecular testing, are
improving the accuracy and speed of diagnosing blood disorders. This leads to
earlier intervention and more effective treatment options. The increasing
prevalence of hematological conditions, including anemia, leukemia, and
lymphoma, fuels demand for innovative therapies. The aging population in Japan
also contributes to market growth, as age-related blood disorders become more
common. Ongoing research and development efforts are leading to the
introduction of novel drugs and targeted therapies, enhancing treatment
outcomes. Increased awareness and improved healthcare infrastructure are also
significant drivers, as they facilitate better access to diagnostic and
therapeutic options for patients. Collectively, these factors contribute to the
expansion and advancement of the Japan Haematology Market.
Key Market Drivers
Advances in Diagnostic Technologies
The rapid advancement in diagnostic technologies is
a transformative force driving the growth of the Japan Haematology Market.
Innovations in diagnostic tools are significantly enhancing the ability to
detect and diagnose hematological disorders with greater precision and speed,
which is crucial for effective management and treatment. These advancements are
not only improving the accuracy of diagnoses but also expanding the range of
available therapies.
Next-Generation Sequencing (NGS) represents one of
the most groundbreaking advancements in diagnostic technology. NGS allows for
comprehensive genomic profiling, which is invaluable in identifying genetic
mutations associated with various blood cancers such as leukemia, lymphoma, and
myelodysplastic syndromes. By analyzing vast amounts of genetic data, NGS
provides insights into the molecular mechanisms underlying these disorders,
enabling the development of targeted therapies tailored to the specific genetic
alterations present in each patient. This level of personalized medicine
enhances the effectiveness of treatments and reduces the risk of adverse side
effects, as therapies can be specifically designed to address the unique
genetic profile of an individual's disease.
Advanced Flow Cytometry is another key
technological advancement. This technique enables the detailed analysis of cell
populations based on their physical and chemical characteristics. Flow
cytometry is instrumental in diagnosing and classifying hematological
malignancies by providing precise information on the number and type of cells
present in a sample. It is particularly useful in distinguishing between
different types of leukemia and lymphoma, as well as in monitoring minimal
residual disease (MRD) to assess the effectiveness of treatment and detect
relapse early. Molecular Assays further contribute to the advancement of
diagnostic capabilities in hematology. These assays detect specific genetic or
molecular markers associated with hematological disorders, allowing for early
and accurate diagnosis. For instance, molecular assays can identify specific
gene mutations or translocations that are characteristic of certain blood cancers,
facilitating a more precise diagnosis and enabling clinicians to choose the
most appropriate treatment options.
Increasing Prevalence of Hematological Disorders
The growing prevalence of hematological disorders
is a crucial driver of the Japan Haematology Market. Various conditions such as
anemia, leukemia, lymphoma, and multiple myeloma are becoming increasingly
common, a trend influenced by factors including an aging population, lifestyle
changes, and improved diagnostic capabilities. Anemia, which affects a
significant segment of the population, is one of the most prevalent
hematological conditions. This disorder, characterized by a deficiency of red
blood cells or hemoglobin, leads to symptoms such as fatigue, weakness, and
shortness of breath. The rising incidence of anemia, particularly among the
elderly and those with chronic diseases, has escalated the demand for
diagnostic testing and effective treatment options. As a result, there is a
growing market for drugs and supplements designed to manage anemia, including
iron supplements, erythropoiesis-stimulating agents, and vitamin B12
injections. According to a WHO report, anemia (defined as hemoglobin [Hb]
< 12 g/dL for non-pregnant women and <11 g/dL for pregnant women)
affected approximately 22% of women of reproductive age (15–49 years) in 2011.
This prevalence places Japan in the second-highest category of public health
significance (20%–39% prevalence), indicating a moderate public health issue.
Japan’s rates are higher compared to other developed nations such as France,
Germany, the United Kingdom, and the United States, and are on par with those
in China and Singapore. Among older adults in Japan, the prevalence of anemia
(defined as Hb < 13 g/dL for men and <12 g/dL for women) is also elevated
compared to other developed countries. Data from the National Health and
Nutrition Survey between 2010 and 2015 report a prevalence of 17.1% in
individuals aged 65 and older, and a study of community-dwelling participants
aged 69–91 years shows a prevalence of 22.3%.
Similarly, the incidence of blood cancers like
leukemia and lymphoma is on the rise. Leukemia, which involves cancer of the
blood-forming tissues, and lymphoma, which affects the lymphatic system, are
being diagnosed more frequently due to improved diagnostic techniques and an
increase in risk factors such as age and environmental exposures. The growing
number of cases necessitates the development of advanced therapeutic solutions,
including targeted therapies, immunotherapies, and chemotherapy regimens. The
increasing need for effective treatments drives pharmaceutical companies and
research institutions to invest heavily in drug development and clinical
trials. Multiple myeloma, another significant hematological disorder, is also
witnessing a rise in prevalence. This cancer of the plasma cells in the bone
marrow can lead to severe complications such as bone damage, anemia, and kidney
problems. The increasing number of diagnosed cases of multiple myeloma
underscores the need for innovative treatment approaches, including novel drugs
and personalized medicine strategies.
Growing Research and Development
The emphasis on research and development (R&D)
within the field of hematology is a major driver of market growth in Japan.
This focus on R&D is transforming the landscape of hematological care
through the discovery of novel drug compounds, optimization of existing
treatment protocols, and exploration of innovative therapeutic approaches. The
active engagement of pharmaceutical companies, academic institutions, and
research organizations is pivotal in advancing the field.
Pharmaceutical companies are heavily invested in
R&D to develop new treatments for various hematological disorders. This
investment is channeled into discovering and developing new drug compounds that
target specific pathways involved in blood disorders such as leukemia,
lymphoma, anemia, and thrombocytopenia. For instance, research into targeted
therapies aims to create drugs that precisely attack cancer cells while
minimizing damage to healthy cells, thereby improving efficacy and reducing
side effects. Such targeted treatments are particularly important for
conditions like chronic myeloid leukemia (CML) and acute lymphoblastic leukemia
(ALL), where precision medicine can significantly enhance patient outcomes. Another
critical area of focus in R&D is optimizing treatment protocols to improve
patient care. This includes refining dosing regimens, enhancing drug delivery
methods, and combining different therapies to achieve better results. For
example, combination therapies that integrate traditional treatments with newer
modalities like immunotherapies or targeted agents are being investigated to
increase their effectiveness. Optimizing treatment schedules and reducing the
frequency of administration can greatly enhance patient adherence and quality
of life.
Expansion of Healthcare Infrastructure
The expansion of healthcare infrastructure in Japan
is playing a pivotal role in driving the growth of the Japan Haematology Market.
Significant investments are being made to enhance healthcare facilities,
incorporate advanced diagnostic technologies, and establish specialized
treatment centers dedicated to managing blood disorders. This infrastructural
development is critical for improving both the availability and quality of
hematological care across the country. Modernizing healthcare facilities
involves upgrading existing hospitals and clinics with the latest medical
technologies and equipment. This includes the introduction of advanced imaging
systems, such as high-resolution MRI and CT scanners, as well as cutting-edge
diagnostic tools specifically designed for hematological conditions. These
upgrades enable more accurate and timely diagnoses of blood disorders,
including leukemia, lymphoma, and various anemias, thereby improving patient
outcomes. The ability to detect these conditions at earlier stages enhances the
effectiveness of treatment and increases the overall success rates of
interventions.
In addition to modernizing existing facilities,
there is a strong emphasis on constructing new healthcare centers that are
equipped with state-of-the-art technology. These new facilities often feature
specialized units for hematology, providing a comprehensive range of services including
diagnostic testing, treatment planning, and ongoing management of blood
disorders. The availability of specialized hematology centers is crucial for
delivering high-quality care, as these centers are staffed by experts with
specific training and experience in managing complex hematological conditions.
This specialization ensures that patients receive the most appropriate and
effective treatments available. The growth of specialized treatment centers and
clinics dedicated to hematology further supports the market by offering focused
expertise and resources tailored to the needs of patients with blood disorders.
These centers often provide a multidisciplinary approach to care, integrating
hematologists, oncologists, nurses, and other healthcare professionals to
deliver comprehensive treatment plans. This approach not only improves patient
care but also enhances the efficiency of treatment processes, leading to better
outcomes and higher patient satisfaction.
Download Free Sample Report
Key Market Challenges
High Cost of Advanced Treatments
The Japan hematology market faces a significant
challenge due to the high cost of advanced treatments and therapies.
Hematological disorders, including various types of blood cancers, hemophilia,
and other rare blood diseases, often require specialized and cutting-edge
treatments. These include targeted therapies, gene therapies, and advanced
biologics, which are typically very expensive to develop and administer. The
high costs are attributed to several factors: the complexity of drug
development, extensive clinical trials, and the need for ongoing research to
optimize and personalize treatment. For instance, gene therapy for conditions
like sickle cell disease or hemophilia involves modifying a patient's genetic
material to address the underlying cause of the disease. This process is not
only technically challenging but also requires substantial investment in
research and development. Similarly, advanced biologics used in treating blood
cancers, such as monoclonal antibodies and CAR-T cell therapies, involve
sophisticated manufacturing processes and high-quality control standards, which
further drive up costs.
The high price of these treatments poses a
challenge for both healthcare providers and patients. For healthcare providers,
the cost constraints can limit the availability of these advanced therapies and
impact their ability to offer the best possible care to all patients. For
patients, the financial burden can be overwhelming, particularly for those who
do not have adequate insurance coverage or financial resources. This disparity
can lead to delays in treatment, suboptimal care, and inequities in access to
advanced therapies, ultimately affecting patient outcomes and overall market
growth. The Japanese government and insurance companies must navigate the
challenge of balancing the need to provide access to these costly treatments
with the constraints of healthcare budgets. While Japan has a robust healthcare
system and universal health coverage, the escalating costs of advanced
hematology treatments create pressure on the system to manage expenditures
while maintaining high standards of care. This balancing act requires careful
planning, negotiation, and policy adjustments to ensure that innovative treatments
are accessible to those who need them without placing an unsustainable
financial burden on the healthcare system.
Limited Availability of Clinical Trial Participants
The limited availability of clinical trial
participants is a significant challenge for the Japan hematology market.
Clinical trials are essential for the development and approval of new
therapies, as they provide critical data on the safety and efficacy of
treatments. However, recruiting sufficient numbers of participants for these
trials can be challenging, particularly for rare or less common hematological
disorders. In Japan, the patient population for many hematological conditions
is relatively small compared to other countries, which can complicate the
recruitment process. For example, rare blood cancers and genetic blood
disorders have limited patient populations, making it difficult to find enough
eligible participants who meet the specific criteria for clinical trials. This
limitation can delay the development of new treatments, hinder progress in
research, and impact the overall growth of the market.
Clinical trials often require participants to meet
stringent inclusion and exclusion criteria, which can further narrow the pool
of eligible patients. Factors such as age, disease stage, and previous
treatment history can restrict the number of patients who qualify for a
particular study. This situation is compounded by the need for patients to
commit to the time and effort required for participation, including multiple
visits, tests, and monitoring. To address this challenge, researchers and
pharmaceutical companies need to explore innovative strategies to enhance
patient recruitment and retention. This may involve leveraging digital
technologies to reach potential participants, collaborating with patient
advocacy groups to raise awareness, and implementing more flexible trial
designs that accommodate a broader range of patients. Expanding the use of
registries and databases to identify and recruit eligible participants can help
streamline the process and improve trial efficiency.
Key Market Trends
Innovations in Drug Delivery Systems
Innovations in drug delivery systems are
significantly transforming the Japan Haematology Market by enhancing treatment
efficacy and patient convenience. Recent advancements include targeted drug
delivery, which allows for precise delivery of medications directly to affected
cells or tissues, minimizing side effects and improving outcomes. For instance,
targeted delivery systems can focus chemotherapy drugs on cancerous cells,
reducing damage to healthy tissue. Sustained-release formulations are another
breakthrough, reducing the frequency of dosing and thus improving patient
adherence and maintaining consistent drug levels in the bloodstream. Novel
administration routes, such as oral formulations and subcutaneous injections,
offer more convenient options compared to traditional intravenous
administration. These innovations not only simplify treatment regimens but also
improve patient compliance. The integration of digital health technologies,
such as smart delivery devices and remote monitoring, further enhances patient
engagement and adherence. Advanced drug formulation techniques, including
nanotechnology-based approaches, improve drug stability and bioavailability,
contributing to more effective treatments. Personalized medicine, which tailors
therapies to individual patient profiles, is supported by these advancements,
leading to better-targeted therapies. Collectively, these innovations are
driving the growth of the v by expanding treatment options and improving
overall patient experiences.
Growing Investments from Biotechnology Firms
The Japan Haematology Market is experiencing
significant growth due to the rising investments from biotechnology firms.
These companies are pivotal in advancing the field of hematology by focusing on
the development and commercialization of cutting-edge therapies for various
blood disorders. Biotechnology firms are heavily investing in research and
development (R&D) to discover new drug candidates, enhance existing
treatments, and create innovative diagnostic tools. This influx of capital is
often driven by the lucrative potential returns and the chance to address substantial
unmet medical needs within the hematology sector. According to a report in
“Clinical performance testing of the automated haematology analyzer XN-31
prototype using whole blood samples from patients with imported malaria in
Japan”, the XN-31 prototype (XN-31p) is an advanced automated hematology
analyzer designed for flow cytometry, specifically developed to quantify and
analyze malaria-infected red blood cells (MI-RBC) as part of a complete blood
count (CBC). Capable of delivering results in approximately one minute, the
XN-31p also identifies the species of the malaria parasite (Plasmodium). This
device has undergone clinical testing using blood samples from patients with
imported malaria in Japan. Blood samples were obtained from 80 patients
who sought malaria diagnosis at the National Center for Global Health and
Medicine in Tokyo, Japan, between January 2017 and January 2019. The results
from the XN-31p were compared with those obtained using standard methods,
including microscopic examination, rapid diagnostic tests, and nested PCR.
Biotech companies are particularly enthusiastic
about exploring innovative approaches such as gene therapy, cell therapy, and
biologics. Gene therapy offers the potential to correct genetic defects
responsible for blood disorders, while cell therapy involves using engineered
cells to treat conditions like leukemia and lymphoma. Biologics, including
monoclonal antibodies and targeted therapies, represent a significant
advancement in treating diseases like multiple myeloma and hemophilia. These
therapies are designed to be highly specific, targeting disease pathways with
greater precision and fewer side effects compared to traditional treatments. The
substantial investment in these advanced approaches accelerates the development
of new therapies and technologies. Biotechnology firms are not only developing
novel treatment options but are also improving the efficacy and safety profiles
of existing drugs. The competitive nature of the biotechnology sector drives
rapid innovation, with companies striving to bring groundbreaking therapies to
market. These investments contribute to expanding the range of treatment
options available to patients with hematological conditions. As biotechnology
firms push the boundaries of what is possible in drug development, they create
opportunities for personalized medicine and targeted treatments that cater to
individual patient needs. The focus on R&D and technological advancements
ensures that the Japan Haematology Market continues to evolve, providing more
effective and tailored solutions for managing complex blood disorders.
Segmental Insights
Product Insights
Based on the Product, hematology
analyzers are the dominant force among various diagnostic instruments,
including flow cytometers, coagulation analyzers, slide strainers, centrifuges,
and hemoglobinometers. Hematology analyzers play a critical role in the
comprehensive analysis of blood samples, providing essential data for
diagnosing and monitoring a wide range of hematological disorders. Hematology
analyzers are advanced instruments designed to perform detailed and automated
blood cell counts and assessments. They are equipped to handle a variety of
tests, such as complete blood counts (CBC), white blood cell differentials, and
platelet counts, among others. These analyzers are vital for detecting
abnormalities in blood cell counts and morphology, which are crucial for
diagnosing conditions such as anemia, leukemia, lymphoma, and other blood
disorders.
The dominance of hematology
analyzers in the market can be attributed to several key factors. Their ability
to provide accurate and rapid results is essential in clinical settings where
timely diagnosis and treatment are critical. The advanced technology
incorporated into modern hematology analyzers allows for high-throughput
processing, which is crucial for hospitals and diagnostic laboratories that
handle large volumes of samples. This efficiency in processing not only
improves the turnaround time for test results but also enhances the overall
productivity of healthcare facilities. Hematology analyzers are integral to the
routine screening and monitoring of hematological conditions. They offer comprehensive
panels that enable clinicians to assess various parameters of blood health,
such as red and white blood cell counts, hemoglobin levels, and platelet
counts. This breadth of analysis supports the accurate diagnosis of a wide
range of disorders and helps in tracking the progression or response to
treatment, making them indispensable tools in the management of hematological
diseases.
Technological advancements
have further solidified the dominance of hematology analyzers. Modern analyzers
incorporate sophisticated features such as flow cytometry-based techniques,
which enhance their capability to provide more detailed and precise analyses.
These innovations have led to the development of analyzers that offer
multiparametric analysis, combining traditional cell counting with advanced
features like automated reticulocyte counts and hemoglobin electrophoresis.
Such advancements cater to the growing demand for comprehensive diagnostic
solutions and align with the evolving needs of the healthcare industry.
Reagents Insights
Based on Reagents, coagulation
reagents are the dominant segment among coagulation reagents, flow cytometry
reagents, and immuno-hematology reagents. This dominance is attributed to their
critical role in diagnosing and managing coagulation disorders, which are
prevalent and require precise and reliable diagnostic tools. Coagulation
reagents are essential for assessing the blood's ability to clot properly,
which is crucial in diagnosing conditions such as hemophilia, von Willebrand
disease, and various types of thrombosis and bleeding disorders. These reagents
are used in a variety of tests, including prothrombin time (PT), activated
partial thromboplastin time (aPTT), and thrombin time (TT), which are
fundamental for evaluating coagulation pathways and identifying deficiencies or
dysfunctions in the blood clotting process.
The prominence of
coagulation reagents in the market can be attributed to several key factors. The
prevalence of coagulation disorders drives significant demand for these
reagents. Disorders related to blood clotting are not uncommon in Japan, and
the need for accurate and efficient diagnostic testing is high. Coagulation reagents
are used in routine clinical practice, hospitals, and specialized laboratories,
making them indispensable in the diagnosis and management of these conditions.
Advancements in coagulation testing technologies have enhanced the capabilities
and applications of coagulation reagents. Modern coagulation analyzers, which
rely on these reagents, have become increasingly sophisticated, offering
improved sensitivity, accuracy, and speed. These technological advancements
have increased the efficiency of coagulation testing, making it possible to
perform a wide range of tests quickly and with high precision. As a result, the
demand for advanced coagulation reagents has grown, reinforcing their dominant
position in the market.
Download Free Sample Report
Regional Insights
The Kanto region stands out as the dominant area.
The Kanto region, which includes Tokyo and its surrounding prefectures such as
Kanagawa, Chiba, and Saitama, leads the market due to several compelling
factors that drive its prominence in the healthcare sector. The Kanto region is
home to Japan’s capital city, Tokyo, which serves as the epicenter of the
country's medical and research institutions. Tokyo is renowned for its advanced
healthcare facilities, cutting-edge research centers, and major pharmaceutical
companies. The concentration of top-tier hospitals, such as the University of
Tokyo Hospital and Keio University Hospital, along with specialized hematology
centers, provides a robust infrastructure for hematology diagnostics and treatment.
These institutions are pivotal in conducting clinical trials, implementing new
technologies, and offering a wide range of hematological services, thereby
boosting the demand for hematology products and services.
The Kanto region benefits from a high population
density and a significant proportion of Japan’s urban population. This
demographic advantage translates into a larger patient base and a higher demand
for medical services, including those related to hematology. The high
prevalence of hematological disorders, coupled with the region's access to
advanced diagnostic and treatment facilities, contributes to the strong market
presence.
The region’s economic strength also plays a crucial
role. As the economic hub of Japan, the Kanto area attracts significant
investment in healthcare and medical technology. Major pharmaceutical and
biotechnology companies have their headquarters or significant operations in
Tokyo and surrounding areas. This concentration of industry leaders facilitates
the development, production, and distribution of hematology-related products,
including diagnostic tools, treatment reagents, and advanced therapies. The
Kanto region’s leadership is further reinforced by its emphasis on innovation
and research. The presence of prestigious academic institutions and research
organizations, such as the RIKEN research institute and various universities,
drives advancements in hematological research and the development of new
therapies. These institutions collaborate with industry stakeholders to advance
hematology science and bring new solutions to market.
Recent Developments
- In March 2024, Otsuka
Pharmaceutical Co., Ltd. (Tokyo), in collaboration with The National Cancer
Center Japan (Tokyo), Kyushu University (Fukuoka), Kyoto University (Kyoto),
Nagoya Medical Center (Aichi), the Advanced Clinical Research Center at The
Institute of Medical Science, The University of Tokyo (Tokyo), and Keio
University School of Medicine (Tokyo), has announced the submission of an
application to the Japanese Ministry of Health, Labour and Welfare (MHLW) for
approval to manufacture and sell a gene panel test for hematological
malignancies in Japan. This prototype, developed collaboratively by Otsuka
Pharmaceutical and the National Cancer Center, has undergone performance
validation by a research consortium that includes the National Cancer Center,
Kyushu University, Kyoto University, and Nagoya Medical Center.
- In January 2024, Takeda, a
Japan-based pharmaceutical company, and Protagonist Therapeutics, a US-based
biotech firm, entered into a global licensing and collaboration agreement to
develop and commercialize rusfertide, an experimental injectable peptide that
mimics the natural hormone hepcidin. Currently in a pivotal Phase 3 trial known
as VERIFY, rusfertide is being evaluated for its efficacy in treating
Polycythemia Vera (PV), a rare chronic blood disorder characterized by
excessive red blood cell production. PV affects approximately 160,000 patients
in the US and a similar number in Europe. Under the terms of the agreement,
Protagonist will receive an upfront payment of $300 million. Protagonist stands
to earn further payments tied to global development, regulatory milestones, as
well as commercial milestones and royalties on net sales outside the US.
Protagonist will oversee research and development until the Phase 3 trial and
US regulatory approval are completed, while Takeda will manage development
outside the US and lead the global commercialization efforts.
- In January 2024, Voydeya
(danicopan) received approval in Japan for treating paroxysmal nocturnal
hemoglobinuria (PNH). It is specifically indicated for use in conjunction with
C5 inhibitor therapy for patients who have not responded adequately to such
treatments. Voydeya is a pioneering, oral Factor D inhibitor designed to be
used as an adjunct to established therapies like Ultomiris or Soliris, catering
to the 10-20% of PNH patients who continue to experience clinically significant
extravascular hemolysis (EVH) despite C5 inhibitor therapy. The Japanese
Ministry of Health, Labour and Welfare (MHLW) granted approval following
positive outcomes from the pivotal ALPHA Phase III trial, with results from the
trial's 12-week primary evaluation period published in *The Lancet
Haematology*.
Key Market Players
- Sysmex Corporation
- Shionogi & Co., Ltd
- Nihon Kohden Corporation
- Siemens K.K.
- Abbott Japan Co., Ltd.
- HORIBA, Ltd.
|
By Product
|
By Reagents
|
By Application
|
By End User
|
By Region
|
- Hematology Analyzers
- Flow Cytometers
- Coagulation Analyzers
- Slide Stainers
- Centrifuges
- Hemoglobinometers
- Others
|
- Coagulation Reagents
- Flow Cytometry Reagents
- Immuno-haematology Reagents
- Others
|
- Drug Testing
- Auto-immune Diseases
- Cancer
- Diabetes Mellitus
- Infectious Diseases
- Others
|
- Hospital
- Clinical Testing Institutes
- Patient Self-testing
- Other End Users
|
- Hokkaido
- Tohoku
- Kanto
- Chubu
- Kansai
- Chugoku
- Shikoku
- Kyushu
|
Report Scope:
In this report, the Japan Haematology Market has
been segmented into the following categories, in addition to the industry
trends which have also been detailed below:
- Japan Haematology Market, By Product:
o Hematology Analyzers
o Flow Cytometers
o Coagulation Analyzers
o Slide Stainers
o Centrifuges
o Hemoglobinometers
o Others
- Japan Haematology Market, By Reagents:
o Coagulation Reagents
o Flow Cytometry Reagents
o Immuno-haematology Reagents
o Others
- Japan Haematology Market, By Application:
o Drug Testing
o Auto-immune Diseases
o Cancer
o Diabetes Mellitus
o Infectious Diseases
o Others
- Japan Haematology Market, By End User:
o Hospital
o Clinical Testing Institutes
o Patient Self-testing
o Other End Users
- Japan Haematology Market, By Region:
o Hokkaido
o Tohoku
o Kanto
o Chubu
o Kansai
o Chugoku
o Shikoku
o Kyushu
Competitive Landscape
Company Profiles: Detailed analysis of the major companies
present in the Japan Haematology Market.
Available Customizations:
Japan Haematology Market report with the
given market data, TechSci Research offers customizations according to a
company's specific needs. The following customization options are available for
the report:
Company Information
- Detailed analysis and
profiling of additional market players (up to five).
Japan Haematology Market is an upcoming report
to be released soon. If you wish an early delivery of this report or want to
confirm the date of release, please contact us at [email protected]